Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 3;14:1159829. doi: 10.3389/fphar.2023.1159829

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Chen, Liu, Chen, Zhang, Tao, Chen, Wang, Sun, Wu and Liu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

JPYZXZ reduced exosomal PD-L1, along with the proportion of MDSCs in the peripheral blood of patients with GC. (A) Exosomal PD-L1 content from the serum of patients with GC. (B) PMN-MDSCs and M-MDSCs gating process in the peripheral blood of patients with GC. Percentage of (C,D) PMN-MDSCs (CD11b⁺CD14⁻CD15⁺) and (E,F) M-MDSCs (CD11b⁺CD14⁺CD15⁻HLA-DR^-/low) in the peripheral blood of patients with GC before and after the JPYZXZ treatment, determined using flow cytometry analysis. (G,H) Correlation analysis of exosomal PD-L1 and MDSCs levels after JPYZXZ treatment. Data are expressed as the mean ± SD. *p < 0.05.